Cheaper generics on the horizon
As patents expire, reporting warns that generic versions of GLP‑1 drugs could sell for as little as $20 a month overseas, a shift described as a “mixed blessing” for countries like Australia. The coverage frames a coming market change that could sharply lower cost of these medicines abroad. (smh.com.au)
Generic versions of some glucagon-like peptide-1 drugs are moving closer in several big markets, and analysts say semaglutide could eventually sell for about $20 a month outside the United States. (iqvia.com) Semaglutide is the ingredient in Ozempic and Wegovy, and patent protection starts to loosen in 2026 in countries including Canada, India, China, Brazil and Turkey, according to IQVIA and industry reporting. In Canada, Novo Nordisk’s core semaglutide patent had already lapsed before data exclusivity ended on January 4, 2026. (iqvia.com) (endorhealth.com) The price forecasts are far below today’s branded levels. In the United States, Novo Nordisk says uninsured or self-pay patients can pay $349 a month for most Ozempic doses after a temporary $199 introductory offer, while other cash-price trackers still put semaglutide near $1,000 a month without coverage. (novomedlink.com) (skinnyrx.com) Glucagon-like peptide-1 drugs work by copying a gut hormone that helps control blood sugar and slows stomach emptying, which can reduce appetite and body weight. That combination turned Ozempic and Wegovy into global blockbusters and pushed demand ahead of supply from 2022 into 2025. (fda.gov) (peptidejournal.org) Australia’s catch is that many diabetes patients already pay much less than global list prices through the Pharmaceutical Benefits Scheme. From January 1, 2026, the maximum co-payment for a general patient fell to 25 Australian dollars and the concessional co-payment stayed at 7.70 Australian dollars. (health.gov.au) (pbs.gov.au) Ozempic is listed on Australia’s Pharmaceutical Benefits Scheme for type 2 diabetes, but broader subsidy for obesity treatment is still being worked through. The Pharmaceutical Benefits Advisory Committee said in March 2026 that any subsidised rollout for obesity should be staged and focused first on high-risk groups. (pbs.gov.au 1) (pbs.gov.au 2) That means ultra-cheap offshore generics would not automatically make Australian patients better off in the same way they could in countries where people now pay full private prices. They could, however, put pressure on future pricing and widen access in markets that have been priced out of the current branded products. (smh.com.au) (iqvia.com) The first crack in the class already arrived with liraglutide, an older daily injection sold as Victoza. The Food and Drug Administration approved the first generic liraglutide in December 2024, and Teva had already launched an authorized generic in June 2024. (fda.gov) (tevausa.com) Supply has also eased since the worst of the shortage. Australia’s Pharmaceutical Benefits Advisory Committee said in March 2026 that the Therapeutic Goods Administration was advising there were no shortages of any glucagon-like peptide-1 medicine as of February 2026. (pbs.gov.au) (tga.gov.au) The next question is not whether cheaper copies can be made, but where patent clocks and reimbursement systems let them in first. In countries where those clocks run out in 2026, the market for these drugs is starting to look less like a luxury product and more like a standard generic medicine. (iqvia.com) (cen.acs.org)
